Galena Biopharma Inc news

   Watch this stock
Showing stories 1 - 10 of about 91   

Articles published

GALE 1.57 -0.05 (-3.09%)
price chart
Why Galena Biopharma, Inc. Stock Crashed By 52% in 2014
The overall market may be on pace to deliver solid gains for investors in 2014, but shareholders in Galena Biopharma (NASDAQ: GALE ) can do nothing but shake their head in disappointment with their stock down 52% for the year.
Related articles »  
Why Galena Biopharma Inc. Stock Sank 13% in November
What: Shares of Galena Biopharma (NASDAQ: GALE ) , a biopharmaceutical company focused on developing immunotherapies to treat cancer, sank 13% in November, based on data from S&P Capital IQ, following a weak earnings report and a questionable ...
Related articles »  
Could Galena Biopharma, Inc. Be Running Out of Money?
Today, we're going to take a closer look at small-cap biopharmaceutical company Galena Biopharma (NASDAQ: GALE ) to get a better bead on what its current cash situation looks like, to determine whether or not it could be running out of money, and to ...
Why Galena Biopharma Inc. Stock Tumbled
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.
Galena Biopharma's (GALE) CEO Mark Ahn on Q2 2014 Results - Earnings ...  Seeking Alpha (registration)
Related articles »  
Galena Biopharma Inc. (GALE) Jumps 6.54% on December 17
Galena Biopharma Inc. ($GALE) was among the biggest gainers on the Russell 2000 for Wednesday December 17 as the stock popped 6.54% to $1.63, representing a gain of $0.1 per share.
Galena Biopharma to Present at the Oppenheimer 25th Annual Healthcare ...
PORTLAND, Ore., Nov. 25, 2014 (GLOBE NEWSWIRE) -- Galena Biopharma, Inc. (Nasdaq:GALE), a biopharmaceutical company developing and commercializing innovative, targeted oncology treatments that address major medical needs across the full ...
Related articles »  
Is It Worth Investing In Galena Biopharma Inc(NASDAQ:GALE), Sequenom, Inc ...
Galena Biopharma Inc(NASDAQ:GALE) announced on December 11 that the preliminary immunohistochemistry (IHC) screening data from the NeuVax(TM) (nelipepimut-S) Phase 3 PRESENT trial had been disclosed at the 2014 San Antonio Breast Cancer ...
Healthcare Sector Movers: Anthem, Inc. (ANTM), Galena Biopharma, Inc. (GALE ...
Galena Biopharma, Inc. (GALE) of the Healthcare sector (Biotechnology) moved by -0.62% since open at mid-day today. Galena Biopharma, Inc. (GALE) is currently at $1.59, has a market cap of 196.80 with a volume of 842,922 shares and a weekly ...
Related articles »  
Galena Biopharma Receives Notice of Allowance of U.S. Patent Application for ...
Galena Biopharma, Inc. (Nasdaq:GALE) is a biopharmaceutical company developing and commercializing innovative, targeted oncology therapeutics that address major medical needs across the full spectrum of cancer care.
Related articles »  
Galena Biopharma Presents HER2 Screening Data Including Preliminary Leica ...
11, 2014 (GLOBE NEWSWIRE) -- Galena Biopharma, Inc. (Nasdaq:GALE), a biopharmaceutical company developing and commercializing innovative, targeted oncology treatments that address major medical needs across the full spectrum of cancer care, ...
Related articles »